The Bottom Line Upfront 💡
DexCom $DXCM ( ▼ 0.24% ) dominates the continuous glucose monitoring market with a beautiful recurring revenue model, but faces mounting competition and Medicare reimbursement pressures starting in 2028. The stock appears fairly valued at current levels, with success hinging on expanding beyond traditional diabetes patients while navigating manufacturing challenges.
Sponsorship
The Final Four Is Set. Place Your Trade.
Kalshi lets you trade on March Madness, elections, economics, and more, all on a federally regulated exchange. Arizona, Michigan, UConn, or Illinois, who's cutting down the nets? Put real money behind your prediction and get $10 free when you sign up.
Strata Layers Chart
Layer 1: The Business Model 🏛️
Imagine if your smartphone could constantly monitor your blood sugar without you ever having to prick your finger. That's essentially what DexCom does – they've turned diabetes management from a medieval torture device (okay, maybe that's dramatic, but finger pricks do hurt) into a sleek, continuous monitoring system.
The Core Business: DexCom makes continuous glucose monitoring (CGM) systems that consist of a tiny sensor inserted under the skin, a transmitter that sends data wirelessly, and either a receiver or smartphone app that displays real-time glucose readings every five minutes. Think of it as a fitness tracker, but instead of counting steps, it's tracking the sugar levels in your blood 24/7.
How They Make Money: It's a beautiful recurring revenue model. Patients need to replace the disposable sensors every 10-15 days (depending on the product), while the transmitter and receiver hardware last much longer. It's like the razor-and-blade model, except instead of shaving cream, you're buying life-changing medical technology.
The Product Lineup:
G7: The flagship product with 10-day wear, 30-minute warm-up (fastest in the market), and no finger-stick calibrations needed
G7 15 Day: The newest addition with 15.5-day wear and industry-leading 8.0% accuracy rating
Stelo: The game-changer launched in August 2024 – the first over-the-counter glucose sensor for people with prediabetes and Type 2 diabetes who don't use insulin
Who Buys This Stuff: Primarily people with Type 1 diabetes (about 2 million in the US) and insulin-dependent Type 2 diabetes patients. But here's where it gets interesting – with Stelo, they're targeting the massive market of 25+ million Americans with prediabetes or non-insulin-dependent Type 2 diabetes.
Key Internal Metrics: The company obsesses over customer additions (they added 600,000-700,000 net customers in 2025), manufacturing yield rates, and sensor accuracy measurements. They also track time-in-range improvements for patients – basically, how much time people spend with healthy glucose levels.
Key Takeaway: DexCom has built a recurring revenue medical device business that's transforming diabetes care from painful finger pricks to seamless continuous monitoring, with massive expansion potential beyond traditional diabetes patients.
Layer 2: Category Position 🏆
DexCom sits pretty as the king of the CGM castle, but the competition is heating up faster than a glucose spike after a donut binge.
The Main Rivals:
Abbott Laboratories (Libre family): The scrappy challenger that's been gaining ground, especially internationally, with lower-cost alternatives
Medtronic (Guardian Connect, Simplera): The old guard trying to stay relevant after spinning off their diabetes business
Traditional players: Roche, LifeScan, and Ascensia still duke it out in the finger-stick world
Market Position: DexCom is the clear leader in the US market, but it's not a cakewalk. Abbott's Libre products have been chipping away at market share, particularly in price-sensitive international markets. The competitive landscape got more interesting (read: challenging) when the FDA expanded Medicare coverage to include "adjunctive CGMs" in December 2021, basically rolling out the red carpet for more competitors.
Recent Competitive Developments:
The Patent Peace Treaty: In December 2024, DexCom and Abbott settled all their patent litigation with a "covenant not to sue" until 2034. Translation: they can focus on innovation instead of lawyers' fees.
The FDA Wild Card: In January 2026, the FDA broadened what qualifies as "general wellness devices," potentially letting consumer tech companies enter the glucose monitoring space with less regulatory hassle. Apple Watch glucose monitoring, anyone?
Competitive Advantages: DexCom's secret sauce includes superior accuracy (that 8.0% MARD on the G7 15 Day is industry-leading), extensive ecosystem integration (works with insulin pumps, Apple Watch, etc.), and nearly two decades of regulatory expertise. Plus, they've got strong brand loyalty – when your product literally helps people avoid diabetic comas, customer switching costs are pretty high.
Key Takeaway: DexCom leads the CGM market but faces intensifying competition from both traditional medical device companies and potentially disruptive consumer tech players entering the wellness space.
Layer 3: Show Me The Money! 📈
DexCom's financials tell the story of a company hitting its stride, though not without some growing pains.
Revenue Breakdown:
Total Revenue: $4.66B in 2025 ↗️ (up 15.6% from $4.03B in 2024)
By Channel: 85% through distributors ($3.96B), 15% direct sales ($703M)
By Geography: 72% US ($3.33B), 28% International ($1.33B)
Customer Concentration: One distributor accounts for 55% of total revenue (that's... a lot of eggs in one basket)
The Growth Story: Revenue has been on a tear, growing from $3.62B in 2023 to $4.66B in 2025. The growth is primarily volume-driven from adding 600,000-700,000 net customers annually, though they're facing pricing headwinds due to increased rebate eligibility and channel mix changes.
Profitability Picture:
Gross Margin: 60.1% in 2025 ↘️ (down from 60.5% in 2024) – some margin compression from manufacturing inefficiencies
Operating Margin: 19.6% in 2025 ↗️ (up from 14.9% in 2024) – impressive operating leverage
Net Margin: 17.9% in 2025 ↗️ (up from 14.3% in 2024)
Cost Structure:
R&D: $599M (12.9% of revenue) – they're not skimping on innovation
SG&A: $1.29B (27.7% of revenue) – includes significant marketing spend ($224M in advertising alone)
Manufacturing: They're dealing with some quality control issues, evidenced by inventory reserve charges of $92.8M in 2025 (nearly double the prior year)
Cash Generation: The company is a cash cow, generating $1.44B in operating cash flow in 2025 ↗️ (up 46% from $989M in 2024). They're sitting on $2.0B in cash and marketable securities, giving them plenty of firepower for growth investments.
The Reimbursement Reality: Most revenue depends on insurance coverage. Medicare competitive bidding starting in 2028 is expected to pressure pricing, while recent healthcare legislation could reduce Medicaid coverage for millions.
Key Takeaway: DexCom delivers strong revenue growth and impressive cash generation, but faces margin pressure from manufacturing challenges and looming reimbursement headwinds starting in 2028.
Layer 4: Long-Term Valuation (DCF Model) 💰
The Verdict: Fairly Valued (with a wide range of possibilities)
Scenario | Fair Value | vs Current Price ($62.25) |
|---|---|---|
Conservative | $38 | -39% ↘️ |
Optimistic | $86 | +38% ↗️ |
Key Valuation Drivers:
Revenue Growth Sustainability: Can they maintain double-digit growth as the market matures and competition intensifies?
Margin Expansion Potential: Operating leverage should drive margins higher, but manufacturing issues and Medicare pricing pressure create headwinds
Terminal Value Assumptions: The wide valuation range ($38-$86) reflects uncertainty about long-term competitive positioning
Recommendation: At $62.25, DXCM appears fairly valued under base case assumptions. The stock offers asymmetric upside if they successfully expand into the broader metabolic health market with products like Stelo, but faces meaningful downside if Medicare reimbursement cuts and manufacturing issues persist.
Layer 5: What Do We Have to Believe? 📚
Bull Case 🚀
Market Expansion Magic: Stelo and future over-the-counter products successfully tap into the 25+ million person prediabetes/non-insulin Type 2 diabetes market, creating a massive new revenue stream
Manufacturing Mastery: They resolve FDA warning letter issues and scale production efficiently across their Arizona, Malaysia, and Ireland facilities
Innovation Leadership: Continued technological advances (longer wear times, better accuracy, ecosystem integration) maintain competitive moats against Abbott and emerging players
Bear Case 🐻
Reimbursement Reality Check: Medicare competitive bidding starting in 2028 significantly pressures pricing, while Medicaid cuts reduce the addressable market
Manufacturing Meltdown: FDA warning letter issues escalate, leading to production restrictions or recalls that damage the brand and financial performance
Competition Intensifies: Abbott continues gaining market share while new entrants (potentially Apple, Google, or other tech giants) disrupt the category with consumer-friendly alternatives
The Bottom Line: DexCom has built an impressive franchise in a growing market, but success hinges on executing a tricky expansion beyond traditional diabetes patients while navigating manufacturing challenges and reimbursement pressures. The company's strong cash generation and market leadership provide a solid foundation, but the wide valuation range reflects genuine uncertainty about the next chapter of growth.
What to Watch 👀
Manufacturing Recovery 🏭: Monitor progress on resolving FDA warning letter issues. Any additional regulatory actions or production disruptions would be major red flags.
Stelo Adoption 📱: Track uptake of the over-the-counter product – this could be the key to unlocking the next phase of growth beyond traditional diabetes patients.
Medicare Bidding Impact 💰: Watch for details on the 2027 competitive bidding process and its impact on 2028 reimbursement rates. This could significantly affect profitability.
Customer Addition Trends 📊: If quarterly net customer additions fall below 150,000-175,000, it could signal market saturation or competitive pressure.
International Expansion 🌍: Monitor progress in European and Asian markets where Abbott has been gaining ground – international growth is crucial for long-term success.
AI-written, human-approved
Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.